Abstract
Background Primary dysmenorrhea (PD) is a gynecological disease that seriously affects women’s physical and mental health and quality of life. Sanyinjiao (SP6) is the most used acupoint for acupuncture treatment of PD, and acupuncture SP6 is more commonly used in the clinical treatment of PD, but evidence of effectiveness and safety is lacking. The purpose of this systematic review plan is to develop a study protocol that can evaluate the efficacy and safety of acupuncture SP6 in the treatment of PD.
Methods The upper limit of retrieval time will be set to September 2023. Foreign and Chinese databases will be searched respectively: Cochrane Library, PubMed, EMBASE, Ovid, Korea Med, J-Global, J-Stage databases, and CNKI, CBM, SinoMed, VIP, Wanfang. Randomized controlled trials meeting the inclusion criteria will be screened by two independent reviewers, and data extraction and risk of bias assessment will be carried out. The primary outcome is dysmenorrhea symptoms, and the secondary outcomes include recent clinical cure rate, concomitant symptoms, serum prostaglandins, uterine artery blood flow resistance under ultrasound monitoring, and adverse reactions. Use RevMan V.5.3 software to perform the following operations: data synthesis, subgroup analysis, heterogeneity analysis, and sensitivity analysis. The evidence quality of clinical studies included in this study will be evaluated by the software of “Grading of Recommendations Assessment, Development, and Evaluation”.
Results This study will provide comprehensive clinical evidence for treating PD with acupuncture SP6.
Conclusion This systematic review will confirm whether acupuncture SP6 is safe and effective in treating PD clinically.
Registration details PROSPERO CRD42020171664.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/
Funding Statement
This study is funded by the National Science Foundation of China (No. 82374512,81674017), http://www.nsfc.gov.cn/.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This study is funded by the National Science Foundation of China (No. 82374512, 81674017), http://www.nsfc.gov.cn/.
Competing interests The authors have no conflicts of interest to disclose.
Availability of data and materials After the completion of the systematic review, all the data extracted from the literature will be published with the publication of the article.
Data Availability
After the completion of the systematic review, all the data extracted from the literature will be published with the publication of the article.
Abbreviations
- PD
- Primary Dysmenorrhea,
- SP6
- Sanyinjiao,
- VAS
- Visual analogue scale,
- TCM
- Traditional Chinese Medicine.
- LOCF
- Last Observation Carried forward,
- NSAIDs
- Nonsteroidal Antiinflammatory Drugs,
- WCA
- Worst Case Analysis.
